Donna Porter, PhD
Administrative Director, UAB Center for AIDS Research (CFAR)
Graduate School: University of Alabama at Birmingham
Post-Doctoral Training: University of Alabama at Birmingham, Dept of Microbiology
- Trained as a virologist with over 25 publications and book chapters during my research career, my early work centered on the development of modified Picornaviruses as a therapeutic delivery system. My research findings led to patented technology used to establish an early stage biotech company (Replicon NeuroTherapeutics, Inc) focused on the treatment of human neurological cancers and disorders.
- As the CFAR Administrative Director, I assume primary responsibility for the management and oversight of all CFAR operations and infrastructure. My service has significantly increased the impact of the UAB CFAR on national and local levels while aiding investigators in the utilization of resources, fostering of multidisciplinary collaborations and the pursuit of HIV/AIDS funding.
- Currently serves as the coordinator for several HIV program projects and networks based at UAB, including the following. Contact me for more information on the utilization of any of the CFAR-related resources.
- CFAR-Network of Integrated Clinical Systems (CNICS)
- Creative and Novel Ideas in HIV Research (CNIHR)
- Women’s Interagency HIV Study (WIHS)
- HIV and Aging Pilot Program in collaboration with Wake Forest University
- CFAR AIDS Malignancy Pilot Program funded by the NCI
- In 2010, I led the implementation of an NCI-funded study to examine the prevalence of HIV among patients with non-AIDS-defining cancers at UAB and within two CNICS sites (UNC and UCSD). Results from the study were presented at a national meeting and a manuscript was published indicating there was no undiagnosed HIV among non-AIDS Defining Cancer (NADC) patients.
- Shrestha, S., D. Johnson, D. C. Porter, E. Reid, J. Palchinsky, S. Napravnik, W. C. Mathews, J. Eron, M. S. Saag. 2013. Lack of Occult HIV infection among non-AIDS-defining cancer (NADC) patients in three academic oncology clinics in the United States. AIDS Research and Human Retroviruses, 29(6):887-91. PMCID: PMC3653389
- Participated in a CNICS-wide study to evaluate the relative benefit of using an efavirenz-based treatment regimen as a single tablet (of FTC/TDF/EFV) versus a separate component in any non-single-tablet form. The primary outcome was time from therapy initiation to virologic failure. The following abstract was presented and published in 2015.
- Daniel R. Drozd, Michael S. Saag, Andrew O. Westfall, Stephen R. Cole, Chris Mathews, Richard Haubrich, Steve Boswell, Donna Porter, Mari M. Kitahata, Timothy Juday, Lisa C. Rosenblatt for the CFAR Network of Integrated Clinical Systems (CNICS), Comparative Effectiveness of Single versus Multiple Tablet Antiretroviral Therapy Regimens in Clinical HIV Practice Presented as Poster at the AMCP's 27th Annual Meeting & Expo in San Diego, CA April 7-10, 2015 and for publication in the Journal of Managed Care & Specialty Pharmacy (JMCP), 2015 Apr;21(4 Suppl A):S10-S11